Clinical Trial: A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07719023) titled 'A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis' on July 17.

Brief Summary: This is a phase 3 clinical study conducted in China. The primary objective is to compare the efficacy and safety of AK3280 400 mg versus placebo and active control (pirfenidone) in IPF patients.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis (IPF)

Intervention: DRUG: AK3280

Participants will receive AK3280 400 mg twice daily, within 30 minutes after breakfast and dinner, with breakfast and dinner approximately 12 hours apart.

DRUG: Placebo

Participants wil...